Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX

So-Heun LEE; Dae-Wook HWANG; Changhoon YOO; Kyu-pyo KIM; Sora KANG; Jae-Ho JEONG; Dongwook OH; Tae-Jun SONG; Sang-Soo LEE; Do-Hyun PARK; Dong-Wan SEO; Jin-hong PARK; Ki-Byung SONG; Jae-Hoon LEE; Woohyung LEE; Yejong PARK; Bong-Jun KWAK; Heung-Moon CHANG; Baek-Yeol RYOO; Song-Cheol KIM.
Cancer Research and Treatment ; : 956-968, 2023.
Artículo en Inglés | WPRIM | ID: wpr-999782

Documentos relacionados

  1. Survival Benefit of Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma Who Underwent Surgery Following Neoadjuvant FOLFIRINOX.
  2. Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysis.
  3. Association of Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma After Multiagent Neoadjuvant Chemotherapy.
  4. Impact of Adherence to Operative Standards and Stage-Specific Guideline-Recommended Therapy in Nonmetastatic Pancreatic Adenocarcinoma.
  5. Association of Medicaid Expansion with Pancreatic Cancer Treatment and Outcomes: Evidence from the National Cancer Database.